Purpose Non-alcoholic fatty liver disease (NAFLD) and associated morbidities have become a major public health problem, with a global three-fold increase in incidence among obese children over the last three decades. Although the gold standard for diagnosis of NAFLD is liver biopsy, it is not widely used in children. Imaging techniques, including magnetic resonance imaging (MRI) and ultrasound (US), can provide information on liver fat deposition, however, with variable sensitivity. A number of other predictors are therefore being investigated for pediatric screening and diagnostic purposes. The aim of this study was to assess easily measured parameters to prompt further investigation into NAFLD in obese children. Methods Obese children/adolescents with a body mass index (BMI) percentile > 95 were enrolled in the study (n = 353). After a 12-hour fast, venous glucose, insulin, cholesterol, triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and uric acid were measured and a full blood count was performed in all subjects. TG/LDL ratio, AST/platelet ratio index (APRI score), and homeostatic model of assessment for insulin resistance (HOMA-IR) were calculated. All patients underwent an abdominal US examination to assess hepatosteatosis. Results Of 353 patients, median age 12.5 (range, 6-17.9) years, 210 patients (59%) had US-proven hepatosteatosis. Female gender reduced the risk of steatosis 2.08-fold (p = 0.005), a one-unit increase in HDL reduced the risk of steatosis 1.02-fold (p = 0.042), and a one-unit increase in BMI led to a 1.11-fold (p = 0.002) increase in the risk of steatosis. Conclusion Gender, BMI, and HDL were found to be predictors of steatosis. Male patients with low HDL and high BMI are at greater risk of steatosis and should be carefully examined for the presence of NAFLD.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a widespectrum metabolic condition characterized by the accumulation of fat in at least 5% of the hepatocytes. It begins as an inflammatory process with steatohepatitis and can progress to fibrosis and end-stage liver disease cirrhosis. Globally, NAFLD is the most frequent cause of chronic liver disease.
It is usually associated with obesity, insulin resistance, metabolic syndrome, and dyslipidemia [1] .
Since definitive identification requires a liver biopsy, which is associated with increased morbidity and is thus often avoided in pediatric patients, prevalence of the condition among children is unclear. Estimates of the prevalence of fatty liver in obese children range between 10 and 77%, while the prevalence of histologically proven NAFLD among obese children in the USA is 38%, the frequency among the normal population being 9% [1, 2] . Ethnic, genetic, and environmental factors are known to play a role in the development of NAFLD and it is more frequently observed among pubertal males and Hispanic men [3] [4] [5] . The pathogenesis of NAFLD may be explained by the well-established double-hit hypothesis. The first hit is insulin resistance, which leads fat to accumulate in the liver resulting in increased free oxygen radicals, the second hit leading to steatohepatitis.
Assessment of liver fat deposition
Magnetic resonance imaging (MRI) can detect hepatosteatosis when fat deposition is ≥ 5%, while ultrasound (US), which is widely used in pediatric patients, has low sensitivity in cases where the fat build-up is below 20% [4, 5] . A quantitative elastographic US technique is still under development [5] . Another method involves the measurement of volatile organic compounds in exhaled breath. Although not very sensitive during childhood, cytokeratin-18 is widely used to detect steatohepatitis [6] . Serum ferritin levels have also been used as a biological indicator to detect NAFLD [7] .
Some scoring systems consisting of clinical and biochemical parameters are also used. The non-invasive fibrosis grading score, the aspartate aminotransferase to alanine aminotransferase (AST/ALT) ratio, AST/platelet ratio, and the fibrosis 4 calculator (FIB-4), using the formula age × AST/platelet × √ALT score, are also in use as non-invasive markers for NAFLD [6, 8] . Recently, a model, constructed using gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), and platelets, was also evaluated [8] , though it requires further development for use in routine practice. In our study, routinely used biochemical and hormonal markers and anthropometric measurements were assessed in order to determine a good, non-invasive marker for the diagnosis of NAFLD.
Materials and methods
All children and adolescents, aged between 6 and 18 years, attending the pediatric endocrinology outpatients clinic of the Samsun Obstetrics-Gynecology and Children's Hospital, Samsun, over a 2-year period (2014-2015) with obesity (as defined by Kurtoglu et al. [9] , see below) were eligible for this prospective study. Exclusion criteria were monogenic obesity, type 2 diabetes, and patients with secondary obesity syndromes and acute or chronic disease. In addition, any patient with an underlying endocrine disease and/or those under medication were excluded from the study.
The approval of the local ethics committee was obtained prior to the commencement of the study. The study was approved by the Ethics Committee of Ondokuz Mayıs University (grant no. B.30.2.ODM0.20.08/1577). Informed consent forms were signed by the parents of the children included in the study.
The height and weight of the children included in the study were measured using standard measuring techniques and the same combined stadiometer/weighing scale (Seca 703 sensitive to 1 mm and accurate to 100 g; SecaGmbH&Co KG, Hamburg, Germany) for all subjects. The ideal body weight percentile of each child was calculated based on the weight and height measurements. Body mass index (BMI) was calculated by dividing weight in kilograms by the square of height in meters (weight [kg]/height squared [m2]). Children whose BMI was above the 95th percentile, according to age, gender, and ethnicity, were classified as obese for the purpose of this study, as previously described by Kurtoglu et al. [9] . (Normal or healty weight was defined as the 5th percentile to less than the 85th percentile for children and adolescents of the same age and sex, and overweight was defined as a BMI at or above the 85th percentile and below the 95th percentile for children and adolescents of the same age and sex. Obesity was defined as a BMI at or above the 95th percentile for children and teens of the same age and sex. Severe obesity was defined as BMI at or above the 99th percentile for children and adolescents of the same age and sex.)
Following a 12-hour overnight fast, venous blood samples were drawn into plain tubes in the morning. LDL, TG, HDL, total cholesterol, VLDL, glucose, and uric acid were tested using a Roche kit on the autoanalyzer. Insulin and thyroid hormone levels were measured by chemiluminescence using a Bio-DPC kit and the Immulite 2000 device. Complete blood count was measured by automated system.
The children selected for the OGTT test were selected on the basis of evidence of insulin resistance, and the OGTT was performed on the basis of clinical need rather than for study purposes. The oral glucose tolerance test was conducted using 1.75 g glucose/kg with a maximum glucose dose of 75 g. The plasma glucose and insulin values were tested on venous blood at 0, 30, 60, 90, and 120 min time points. Insulin resistance was calculated based on the homeostasis model assessment of insulin resistance method (HOMA-IR; fasting insulin μu/L × fasting glucose mmol/L/22.5). Subjects with HOMA-IR > 3.16 were considered to be insulin-resistant, as previously described by Sahin et al. [10] . Cumulative total insulin was calculated as previously described [9] . Briefly, the measured insulin at each time point in the OGTT was added together for each patient. If this cumulative value, hereafter referred to as "total insulin," exceeded 300 μU/ml, then the patient was considered to have hyperinsulinemia. Those with fasting HDL levels ≤ 40 mg/dL and fasting TG levels ≥ 110 mg/dL were considered dyslipidemic [3, 4] .
Thyroid function was analyzed. Serum-free thyroxine (fT4) concentration was measured by radioimmunoassay and thyroid-stimulating hormone (TSH) was measured by immunochemiluminescence on the DPC immulite analyzer (Diagnostic Products Immulite, Diagnostic Products Corp., Los Angeles, CA, USA).
All patients underwent abdominal US examinations by the same radiologist using the SSA-660A Xario Toshiba US device, (Toshiba Inc., Tokyo, Japan) with a 3.5-MHz convex probe for hepatobiliary US. US-proven hepatosteatosis was graded as follows:
Grade 0-Normal parenchymal liver echogenicity by comparison with the right renal cortex [5] . Grade I-mild diffuse increase in echogenicity; the diaphragm and the intrahepatic blood vessel walls appear normal. Grade II-moderate increase in echogenicity; the diaphragm and the intrahepatic blood vessel walls are slightly obscured. Grade III-distinct increase in echogenicity; the diaphragm, intrahepatic blood vessel walls, and the posterior view of the right lobe are severely or totally obscured.
All patients were evaluated by physical examination, hepatic markers, serum ferritin and ceruloplasmin concentrations, and liver-specific autoantibodies.
Statistical analysis
Data were analyzed using the Statistical Package for Social Sciences (SPSS) for Windows, version 22.0 (SPSS Inc, Chicago, IL., USA) software. Descriptive statistics were reported as mean ± standard deviation, median (minimum-maximum), distribution of frequency, and percentage. The AST to platelet ratio index calculator (APRI) score was calculated based on the formula (AST level/AST upper limit of normal/platelet count x100). Categorical variables were evaluated using Pearson's chi-square test and Fisher's exact test. Normal distribution of data items was assessed using visual (histogram and graphics) and analytic methods (the Kolmogorov-Smirnov test). For nonparametric data, the Mann-Whitney U test was used to evaluate the statistical significance between two independent groups. In the multivariate analysis, the independent predictors of US-proven hepatosteatosis were assessed through a logistic regression analysis using the probable factors specified in the previous analyses. The model fit was analyzed with the Hosmer-Lemeshow test. The decisiveness of the variables, BMI and HDL, in predicting US-proven hepatosteatosis were analyzed using receiver operating characteristics (ROC) curve analysis. In the case of significant boundary values, the sensitivity, specificity, and positive and negative predictive values of these boundaries were calculated. Statistical significance was accepted when p < 0.05.
Results
For the study, 353 obese children and adolescents were investigated. The median age of the subjects was 12.5 (6-17.9) years, and 58.1% (n = 205) were aged 12 or above. 54.4% (n = 192) of the subjects were female, while 45.6% (n = 161) were male. The patients' height and body weight were measured and the SDS of their body mass index (BMI-SDS) were calculated. Based on this, the median BMI-SDS of the subjects was 2.55 (range, 1.20-2.58). Among the children/ adolescents included in the study, 59.5% (n = 210) had USproven hepatosteatosis, while 41.9 (n = 148) did not. Among the patients with US-proven hepatosteatosis, the majority, 80.5% (n = 169) were grade I, while 18.1% (n = 38) were grade II, and 1.4% (n = 3) were grade III. The distribution of certain descriptive characteristics among the patients with and without US-proven hepatosteatosis are presented in Table 1 .
Among the children/adolescents investigated for the purposes of the study, 70.2% of the males (n = 113) had USproven hepatosteatosis, while the condition was observed in only 50.5% of females (n = 97). There was a statistically significant difference between sex and the presence of USproven hepatosteatosis (p < 0.001). The median ages and BMI-SDS values of those with US-proven hepatosteatosis were significantly higher than those without (p = 0.004 and p = 0.002, respectively). However, no statistically significant difference in terms of birth weight was observed between the subjects with US-proven hepatosteatosis compared with those without (p > 0.05) ( Table 1) .
The laboratory results, the HOMA-IR values, and the OGTT status of the study subjects with or without USproven hepatosteatosis are presented in Table 2 .
Uric acid, AST, ALT, APRI score, TG, TG/HDL, VLDL, insulin, and the HOMA-IR values of the children and adolescents with US-proven hepatosteatosis were significantly higher than those without hepatosteatosis, while the AST/ ALT ratio and HDL values were significantly lower (p < 0.05). No significant difference was observed between those with or without US-proven hepatosteatosis when TSH, free T4, platelet count, LDL, and fasting blood glucose (FBG) were compared (p > 0.05) ( Table 2) .
Among the 353 children/adolescents recruited, 142 (40.2%) underwent OGTT. Of the latter 142, 76.1% (n = 108) had USproven hepatosteatosis, while 64.4% (n = 85) did not. A statistically significant difference was observed between the OGTT results and the presence of US-proven hepatosteatosis (p = 0.035). The ratio of the hepatosteatosis subjects was higher among those who had OGTT tests ( Table 2) . The total insulin levels of the 108 children/adolescents with US-proven hepatosteatosis who had undergone OGTT and of the 34 children/adolescents without US-proven hepatosteatosis were similar (p > 0.05). Patients with total insulin levels < 300 μU/ml and those with levels ≥ 300 μU/ ml were compared. 52.6% (n = 10) of the subjects who had undergone OGTT and had total insulin levels below 300 μU/ ml had US-proven hepatosteatosis, while 79.7% (n = 98) of the subjects who had undergone OGTT and had total insulin levels ≥ 300 μU/ml were steatotic. A statistically significant difference was observed in terms of the presence of hepatosteatosis by US when subjects were compared according with these groupings (p = 0.018, see Table 2 ).
The independent efficiency of certain predictors specified after previous paired comparisons in predicting US-proven hepatosteatosis were evaluated using logistic regression analysis. The results are presented in Table 3 .
Based on these results, BMI and HDL are good predictors of US-proven hepatosteatosis, while age, uric acid, AST, ALT, triglycerides, VLDL, and HOMA-IR are poor predictors. Female gender reduces the risk of US-proven hepatosteatosis 2.08-fold and a one-unit increase in HDL reduces the risk of steatosis 1.02-fold, while a one-unit increase in BMI leads to a 1.11-fold increase in the risk of steatosis (Table 3) .
The diagnostic utility of BMI and HDL in predicting USproven hepatosteatosis among the subjects was investigated using a ROC curve analysis. The results showed that BMI and HDL have significant diagnostic value in predicting steatosis (AUC BMI , 0.667; 95% CI, 0.610-0.723; p < 0.001; AUC HDL , 0.600; 95% CI, 0.540-0.659; p = 0.001) (Fig. 1) .
The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of BMI and HDL, according to the predetermined cut-off values, are presented in Table 4 . As a predictor of US-proven hepatosteatosis, the sensitivity of BMI for a cut-off value of 25.05 is 87.1%, its specificity is 25.9%, the PPV is 63.3%, and the NPV is 7.8%, while they are 62.4%, 61.5%, 70.4%, and 52.7%, respectively, for a cut-off value of 20.05. The sensitivity of HDL in predicting USproven hepatosteatosis for a cut-off value of 47.02 U/l is 64.8%, its specificity is 47.6%, the PPV is 64.5, and the NPV is 47.9%, while they are 71.4%, 36.4%, 62.2%, and 46.4% respectively, for a cut-off value of 49.05 U/l (Table 4) .
Discussion
NAFLD has become a serious problem among overweight/ obese children in recent years. Since liver biopsy is an invasive method, non-invasive and reliable biochemical markers for the detection of NAFLD have been investigated. The aim of this study was to evaluate the efficacy of commonly measured parameters in obesity to predict the diagnosis of NAFLD.
US can be used to identify patients with NAFLD, especially if they have high ALT concentrations, but evidence suggests that ALT alone is not sensitive enough to distinguish patients with NAFLD generally. We have found that BMI, HOMA-IR, ALT, APRI score, and TG/HDL are significantly different in the two groups (obese with HS and without HS) based on the presence of US-proven hepatosteatosis, but regression analysis indicated BMI, gender, and HDL concentration were the most sensitive markers for identifying patients at greater risk of NAFLD.
One of the main results of our study is that the prevelance of US-proven fatty liver is greater among males compared with females. There are various possible explanations for this. It is well known that higher estrogen levels in women lead to the deposition of fat on hips [11] . This factor could protect females from visceral fat deposition and thus from NAFLD. In a study conducted in 2016, 73% among the 41 pediatric patients with NAFLD verified through biopsy were male and it was proposed as a predictive marker [12] . Another pediatric study published in 2005 reported significantly more NAFLD among males [13] . In males, fat is largely deposited in the omentum and mesentery and, as might be expected, this leads to accompanying hepatosteatosis. Sex hormones do not only affect fat distribution. They also change the distribution of [14] . In patients with polycyctic ovarian syndrome, reduced sex hormone binding globulin and increased free androgens increase the tendency for NAFLD and insulin resistance [15, 16] . Although the relationship between NAFLD and gender is not as well established in children and adolescents compared with adults, there is a clear male predominance in many published reports. However, there have been pediatric reports that did not observe any relationship between gender and NAFLD [17] . In a study from Germany [18] , 16,390 overweight and obese children were evaluated and NAFLD (defined as transaminases > 50 units/l) was found to be 2-fold higher in male patients. These authors also report an age effect, with children and adolescents ≥ 12 years of age being 50% more likely to have NAFLD than those aged < 12 years. They suggest that males are more prone to visceral fat accumulation and thus to NAFLD. This large series demonstrated that male gender is a very strong risk factor for NAFLD in children, as in adults, which is consistent with our findings. Neither pubertal status nor age groupings were assessed in relation to US-proven hepatosteatosis in our study, as the aim was to identify broadly applicable biomarkers triggering further investigation into NAFLD. Increased waist circumference (WC) is considered an indicator of visceral fat [19] . Recent reports indicated that WC to height/waist-to-height ratio in adults is a more sensitive measure than WC alone [20] . In children, WC is not a good predictor for detection of metabolic status, and a recent metaanalysis of 30 studies found no advantage of WC over BMI to predict cardiovascular risk in children and adolescents [21] .
BMI is one of the most important markers of visceral fat accumulation and, consequently, of NAFLD. In our study, besides an expected strong correlation between BMI and NAFLD, it was also observed that each one-unit increase in BMI leads to a 1.11-fold increase in the risk of NAFLD. In another study from Turkey, the most important metabolic predictor of NAFLD in adolescents was found to be BMI [22] , and being overweight was also an important risk factor for fatty liver. In another study conducted on adults in Egypt, the strongest predictor of NAFLD was BMI and the cut-off value was found to be 22.4 [23] . In our study, the most sensitive cut-off for BMI was 25.05 (sensitivity 87%), although specificity (26%) was low. There are also other pediatric studies pointing to a stronger positive correlation between higher ALT levels in association with a higher BMI and NAFLD [24] . NAFLD was found in 77% of obese Chinese children. BMI and ALT levels were reported as independent risk determinants.
High ALT levels may not always correlate with clinical presentation. In a study by Eminoglu et al. [25] , 53% of 101 obese children had NAFLD, while only 13.8% among these had elevated ALT. Fu et al., in a study of 75 children, found that only 25% had high liver enzymes, while 52% had USGindicated fatty liver [26] . An Italian group found BMI-SDS, ALT, serum uric acid, and OGTT insulin and glucose levels to be the most prominent predictors, with most of the prediction being due to BMI and ALT in a cohort of Italian children [27] . Uslusoy et al. [28] have reported that ALT may be normal even in adult patients with severe steatosis. Although high ALT levels are associated with reduced insulin sensitivity and glucose intolerance, it still is not a strong predictor. Similarly, we could not demonstrate a positive correlation between the presence of US-proven hepatosteatosis and serum ALT concentration. However, higher ALT levels are more valuable in detecting progression from hepatosteatosis to steatohepatitis than the diagnosis of NAFLD.
In a further study from Turkey, the frequency of NAFLD was found to be 11% in obese pediatric patients, and a strong correlation between the TG levels and NAFLD was shown [13] . Fu et al. reported non-HDL hyperlipidemia to be the strongest predictor of NAFLD, while recommending routine liver US in all obese children [26] .
The significantly lower concentrations of HDL measured in the NAFLD group, in comparison to the group of obese patients without fat build-up, have been proposed as a predictive marker. This suggestion is strengthened by the results of the logistic regression and ROC curve analyses of our data. Reports on large series of pediatric and adolescent patients have demonstrated that non-HDL-C levels are higher in the group with steatitis compared with the group with simple fat build-up [21, 29] . Dyslipidemia is demonstrable very early in the development of insulin resistance [30] . Ozkol et al. suggested low HDL as an independent predictor in NAFLD in Turkish adolescents, which is consistent with our findings [22] . The prediction value increases when the cut-off value is taken as 47 mg/dl for HDL-C. Elevated non-HDL-C was reported to be a sensitive marker of NAFLD in children in a study from the USA in 2014. It was also reported that non-HDL-C had a positive association with histologic features of non-alcoholic steatohepatitis (NASH) [18, 31] . The apparent discrepancies between the findings of the studies described above may be due to a number of factors. This must include variability in study populations in term of age, gender distribution, and ethnicity, all of which have been shown to affect the risk of NAFLD [2] . In addition, the gold standard for diagnosing NAFLD is a liver biopsy, although this is rarely performed in the pediatric age group, so that diagnosis of NAFLD is often dependent on imaging techniques, which have variable sensitivity for estimating liver fat disposition [5] . Therefore, pediatric study cohorts, including this one, may not be investigating homogeneous populations with NAFLD, as the gold standard diagnosis has not been performed. Schwimmer et al. investigated the prevalence of fatty liver (defined as ≥ 5% of hepatocytes containing macrovesicular fat) by histological examination of pediatric and adolescent samples using autopsy material [2] . They showed an overall prevalence of 13% in all subjects, rising to 38% in the obese. However, since in this study the population was from the USA in 2006 and the study is now 13 years old, it may no longer even reflect the situation in the USA.
Biochemical markers of NAFLD, such as transaminases, and in particular ALT [25] [26] [27] , non-HDL cholesterol [21, 26, 29] , HDL cholesterol [22] , triglycerides [13] , and various models using combinations of these, have been used as predictors of NAFLD. Many of these studies have also reported discrepancies between biochemical markers and imaging results in both children [25] [26] [27] and adults [28] . This again implies that the populations being studied may not be homogeneous for NAFLD.
Limitations of the study were that NAFLD was not verified via histopathologic investigation, as in many earlier pediatric studies, and MRI was also not performed. All children were evaluated with US performed by the same experienced specialist, although patients were not stratified by grade of USproven hepatosteatosis, but were classified as having US evidence of either no degree of fat deposition. Pubertal staging was not performed and thus the influence of sex hormone elevation in puberty and gender differences due to this could not be assessed. We did not use WC to predict NAFLD.
In conclusion, NAFLD is a common complication among obese children, which can be screened for with US. In the hands of an experienced radiologist, it is an effective, noninvasive, commonly available, and repeatable imaging technique for the assessment of NAFLD. In the outpatient clinic, low HDL, male gender, and elevated BMI should lead to a low threshold for US imaging.
